United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 12

Name: Pharmaceutical Preparations Stocks in USA: Revenue Cohort 12 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderKaryopharm · 49

Strongest available pathTheravance Biopharma · +105.3%

Widest latest marginTheravance Biopharma · 98.5%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1KPTI · Nasdaq

Karyopharm

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Natick, Massachusetts$42.4M market cap

View full Companies Radar profile

49Cautious

Snapshot price$1.87as of page date

Monthly-close return-97.8%five-year window

FY2025 revenue$0.15BKaryopharm Therapeutics Inc.

Net margin-134.2%FY2025

P/E snapshot-0.7xone ratio, not a verdict

Prism attention24.4%share across these five

Filing track recordRevenue, USD billions

-30.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.7%

52-week position1% through range

$1.79$10.99

News mentions1.3K

Community mentions22partial coverage

U.S.-scope patents368

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position3/100
Capital-event signal60/100
Innovation pulse14/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 16 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2HRTX · Nasdaq

Heron Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1983Redwood City, California$62.0M market cap

View full Companies Radar profile

47Cautious

Snapshot price$0.33as of page date

Monthly-close return-97.2%five-year window

FY2025 revenue$0.15BHERON THERAPEUTICS, INC. /DE/

Net margin-13.0%FY2025

P/E snapshot-3.0xone ratio, not a verdict

Prism attention12.8%share across these five

Filing track recordRevenue, USD billions

+79.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.7%

52-week position2% through range

$0.30$1.58

News mentions688

Community mentions53partial coverage

U.S.-scope patents227

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal73/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3TBPH · Nasdaq

Theravance Biopharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2001Francisco$885.2M market cap

View full Companies Radar profile

46Cautious

Snapshot price$17.05as of page date

Monthly-close return+105.3%five-year window

FY2025 revenue$0.11BTheravance Biopharma, Inc.

Net margin98.5%FY2025

P/E snapshot16.4xone ratio, not a verdict

Prism attention21.2%share across these five

Filing track recordRevenue, USD billions

+94.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.1%

52-week position50% through range

$13.08$21.03

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents1598

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position8/100
Capital-event signal34/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 7 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4GYRE · Nasdaq

Catalyst Biosciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2002San Diego, California$698.8M market cap

View full Companies Radar profile

43Cautious

Snapshot price$6.59as of page date

Monthly-close return-90.3%five-year window

FY2025 revenue$0.12BGYRE THERAPEUTICS, INC.

Net margin8.5%FY2025

Prism attention10.5%share across these five

Filing track recordRevenue, USD billions

+456.6%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 53.6%

52-week position29% through range

$5.44$9.42

News mentions567

Community mentions5partial coverage

U.S.-scope patents306

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal45/100
Management stability90/100
Market position14/100
Capital-event signal59/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 3 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5MGNX · Nasdaq

MacroGenics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Rockville, Maryland$263.1M market cap

View full Companies Radar profile

34Cautious

Snapshot price$4.13as of page date

Monthly-close return-82.7%five-year window

FY2025 revenue$0.15BMACROGENICS INC

Net margin-49.9%FY2025

P/E snapshot-3.6xone ratio, not a verdict

Prism attention31.1%share across these five

Filing track recordRevenue, USD billions

+93.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.9%

52-week position75% through range

$1.29$5.08

News mentions1.7K

Community mentions29partial coverage

U.S.-scope patents1782

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position3/100
Capital-event signal42/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Theravance Biopharma

+105.3%

MacroGenics

-82.7%

Catalyst Biosciences

-90.3%

Heron Therapeutics

-97.2%

Karyopharm

-97.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Heron Therapeutics

$0.15B

MacroGenics

$0.15B

Karyopharm

$0.15B

Catalyst Biosciences

$0.12B

Theravance Biopharma

$0.11B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Theravance Biopharma

98.5%

Catalyst Biosciences

8.5%

Heron Therapeutics

-13.0%

MacroGenics

-49.9%

Karyopharm

-134.2%

Prism news attention

Normalized share across these five names; attention is not quality.

MacroGenics

31.1%

Karyopharm

24.4%

Theravance Biopharma

21.2%

Heron Therapeutics

12.8%

Catalyst Biosciences

10.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

MacroGenics leads the conversation

It holds 31.1% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.15B.

Price path

Theravance Biopharma leads the available price paths

Its monthly-close return is +105.3% for the five-year window. At the other end, Karyopharm is -97.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Theravance Biopharma has the widest latest margin

Its FY2025 net margin is 98.5%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

MacroGenics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -3.6x while its five-year window price return is -82.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KPTI

Karyopharm

1,313available Prism news records

Prism top themes

Legal, arbitration & regulatory

Capital allocation & transactions

Price action & investor response

Leadership & governance

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-0.5%182 latest 12m vs 183 prior 12m

Machine-classified coverage tone

92.9% positive-2.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 16checkpoint inhibitors lymphoma 7phase iii trial 6immunomodulatory drugs 5car-t myeloma 5stem cell transplant myeloma 5cancer biomarkers 4phase ii trial 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-06-08–2026-06-12 · trend and themes shown through 2026-06

Areas of research · TBPH

Theravance Biopharma

1,141available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+0.9%117 latest 12m vs 116 prior 12m

Machine-classified coverage tone

77.9% positive-13.7 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 22stock price 15share price 9stock surge 5earnings per share 5investment deal 4rare disease treatment 4gene therapy rare diseases 4

Keyword tag occurrences in available Prism news records.

Coverage: 2013-04-26–2026-07-16 · trend and themes shown through 2026-07

Areas of research · MGNX

MacroGenics

1,666available Prism news records

Prism top themes

Legal, arbitration & regulatory

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-60.0%177 latest 12m vs 442 prior 12m

Machine-classified coverage tone

88.4% positive+33.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

class action securities litigation 35cancer biomarkers 33angiogenesis inhibitors 27adc therapeutics 22minority shareholder protections 19derivative lawsuit defense 14shareholder oppression claims 14stock performance 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-01 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

HRTX

Heron Therapeutics

53 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 53 records remained after filtering.

MGNX

MacroGenics

29 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 29 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

KPTI

Karyopharm

through 2026-04-21

Company announcements 37Earnings releases 20Leadership changes 1Listing / IPO 1

2026-04-21
Company announcements
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) said its Phase 3 SENTRY trial in frontline myelofibrosis has been selected for a late-breaking oral presentation at the 2026 American Society of Clinical Oncology annual meeting, giving the small-cap oncology company a larger scientific stage just weeks after reporting topline data.
2026-02-12
Earnings releases
Total revenue for the year ended December 31, 2025 was $146.1 million, compared to $145.2 million for the prior year.
2025-02-14
Listing / IPO
Karyopharm Therapeutics Inc. is seeking to raise up to $80 million from a proposed IPO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

HRTX

Heron Therapeutics

through 2026-02-12

Earnings releases 24Leadership changes 11Company announcements 2Listing / IPO 2

2026-02-12
Leadership changes
Prior to joining Connect Biopharma, he served as the Chief Executive Officer of Heron Therapeutics, Inc. from May 2013 to April 2023, and served as a director of Heron from June 2012 to April 2023.
2026-01-09
Earnings releases
Preliminary Fourth Quarter and Full Year 2025 Updates Net revenue of approximately $40.5 million for the three months ended December 31, 2025.
2025-02-14
Listing / IPO
Heron Therapeutics Inc.'s planned underwritten public offering is expected to gross $119 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TBPH

Theravance Biopharma

through 2026-04-13

Earnings releases 26Asset acquisitions 5Leadership changes 4Lawsuits 1

2026-04-13
Earnings releases
Analysts at Zacks Research issued their Q1 2028 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter.
2025-06-06
Lawsuits
On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution.
2025-06-03
Asset acquisitions
Theravance Biopharma, Inc. (NASDAQ: TBPH) has reached a definitive agreement to sell its remaining royalty interest in Trelegy Ellipta to GSK plc (NYSE: GSK) for $225 million in cash.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GYRE

Catalyst Biosciences

through 2025-02-14

Listing / IPO 2Lawsuits 1M&A 1

2025-02-14
Listing / IPO
Catalyst Biosciences Inc. closed its public offering of units for gross proceeds of $20.7 million.
2023-03-30
Lawsuits
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. (NASDAQ:CBIO), in connection with the proposed purchase of GNI Group Ltd.'s ("GNI") proprietary new chemical entity F351 ("F351")
2023-03-30
M&A
Catalyst Biosciences, Inc. (NASDAQ: CBIO )'s merger with GNI Group Ltd.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MGNX

MacroGenics

through 2026-03-09

Earnings releases 9Lawsuits 6Leadership changes 5Listing / IPO 2Asset acquisitions 1

2026-03-09
Earnings releases
Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027.
2025-09-24
Leadership changes
MacroGenics promoted Eric Risser to president and CEO.
2025-02-14
Business contracts
Macrogenics Inc., of Rockville, Md., has signed agreements with Gilead Sciences Inc., of Foster City, Calif.; with Suresnes, France-based Servier SA; with Boehringer Ingelheim GmbH, of Ingelheim, Germany; and with Pfizer Inc., of New York.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 56–63. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Karyopharm leads the readiness ranking

Its Prism readiness score is 49/100, the highest in this five-company comparison.

Open Karyopharm in Companies Radar

Scale and margin leadership sit with Heron Therapeutics and Theravance Biopharma

Heron Therapeutics has the largest displayed latest revenue at $0.15B; Theravance Biopharma has the widest displayed latest margin at 98.5%.

Open Heron Therapeutics in Companies Radar Open Theravance Biopharma in Companies Radar

Comparisons

Strongest versus weakest available price path

Theravance Biopharma is +105.3% for its five-year window; Karyopharm is -97.8% for its five-year window.

Open Theravance Biopharma in Companies Radar Open Karyopharm in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.15B for Heron Therapeutics to $0.11B for Theravance Biopharma. Entity and filing-period labels remain visible on the company cards.

Open Heron Therapeutics in Companies Radar Open Theravance Biopharma in Companies Radar

Anomalies

MacroGenics has the widest attention-readiness rank gap

It ranks #1 by measured news attention (31.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open MacroGenics in Companies Radar

Catalyst Biosciences shows a price-operating divergence to inspect

Its displayed filing-revenue change is +456.6% while its available monthly-close return is -90.3%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Catalyst Biosciences in Companies Radar

Explanations

Attention measures coverage volume, not quality

MacroGenics's 31.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open MacroGenics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Karyopharm's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open Karyopharm in Companies Radar

Stress-test the largest divergence before forming a view

Compare Catalyst Biosciences's profile with Theravance Biopharma's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Catalyst Biosciences in Companies Radar Open Theravance Biopharma in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.